Loading stock data…
LLY
$934.60+83.39 (+9.80%)
Market ClosedLast close Apr 30
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eli Lilly and Company in the Healthcare sector is trading at $934.60. The stock is currently 18% below its 52-week high of $1,133.95, remaining 2.9% above its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why LLY maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$934.60
Potential Downside
29.3%
Whystock Fair Value$660.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus29 analysts
Buy
Mean target$1202+28.6%
Range$850.00 – $1500
Fundamentals
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$824.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Strong income play. Yield provides a meaningful total return floor.
69.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
52.01%
Volume
Today's trading volume
8.21M
Recent News
Eli Lilly Rises on FDA Compounding Proposal
Plan could limit cheaper copies of GLP-1 weight-loss drugs.
Eli Lilly, Novo Stocks Jump as FDA Moves to Limit Compounded GLP-1 Drugs
FDA Shake-Up Sends Eli Lilly, Novo Nordisk Stocks Higher on Supply Shift
Stock Market Today: Dow Adds 800 Points; Meta Falls, Lilly Jumps As Chip, Data Center Firms Jam (Live Coverage)
Stock Market Today: The Dow Jones index rose Thursday after key inflation data. Meta stock plunged on earnings.
Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales
Eli Lilly shares soars as sales for its GLP-1 drugs outperform.
Earnings live updates: Eli Lilly stock jumps as weight-loss drugs boost results, Caterpillar rises, Google surges
Earnings season is in full swing, with five of the "Magnificent Seven" reporting first quarter results this week